SII B.1.351 - Novavax
Alternative Names: Monovalent B.1.351 [Beta] variant strain vaccine; SII B.1.351Latest Information Update: 28 Apr 2025
At a glance
- Originator Novavax
- Class COVID-19 vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in USA (IM, Injection)
- 31 May 2022 Novavax withdraws prior to enrolment a phase I/II trial for COVID-2019 infections (Prevention) in Australia (IM) (NCT05029856)
- 03 Mar 2021 Preclinical trials in COVID-2019 infections (Prevention) in USA (IM)